RESTON, VirginiaA new national clinical study known as
LAMP (locally advanced multimodality protocol) will help evaluate the
best manner in which to give patients radiation and chemotherapy to
treat locally advanced, non-small-cell lung cancer (NSCLC). The
trial, conducted by the American College of Radiology (ACR), is using
the chemotherapy agents paclitaxel (Taxol) and carboplatin (Paraplatin).
A number of studies of patients with stage III lung cancer show
that many patients benefit from chemotherapy and radiation together,
said Walter J. Curran, Jr., MD, one of the chairs for the study.
Now, we are seeking to refine the manner in which to give the
agents to improve their effectiveness and safety.
The key question to be answered in this clinical trial, he said, is
how best to integrate the radiation and chemotherapy. The options
include giving the two therapies at the same time, giving them one
after the other, or giving the chemotherapy both before and during
radiation therapy, Dr. Curran said.
The LAMP study will evaluate the relapse-free survival rates and
actual survival rates of the various schedules, as well as safety and
toxicity. To obtain more information about LAMP, call Elaine Pakuris